Literature DB >> 9358103

Prognostic value of serum HIV-RNA levels at virologic steady state after seroconversion: relation to CD4 cell count and clinical course of primary infection.

C Pedersen1, T Katzenstein, C Nielsen, J D Lundgren, J Gerstoft.   

Abstract

The objectives of this study were to evaluate the prognostic value of a single serum HIV-RNA measurement 6-24 months after HIV seroconversion, and to investigate whether any differences in outcome related to the clinical course of primary infection could be explained by presumed steady-state HIV-RNA levels at 6-24 months after seroconversion. Disease progression was analyzed by life tables and Cox proportional hazard models. A total of 93 HIV seroconverters followed for a median of 76 months (range, 19-143 months) were included in the study. The main outcome measures were development of AIDS stratified by age, the year of seroconversion, serum HIV-RNA levels, CD4 cell counts, and duration of primary illness. The proportion of patients who developed AIDS was 36% (95% confidence interval, 22%-50%) at 8 years and 50% (26%-75%) at 10 years. In the unadjusted analyses, clinical progression was significantly associated with serum HIV-RNA levels, CD4 cell counts, and duration of primary illness. The adjusted analyses indicated that HIV-RNA was the strongest predictor. Patients with long-lasting symptoms associated with primary infection had significantly higher serum HIV-RNA levels than those with less severe presentations (median counts, 11,660 vs. 2880 copies/ml, p = 0.001). It is concluded that the serum HIV-RNA level in early HIV infection is a strong independent predictor of clinical progression. Patients with long-lasting primary illnesses reach a higher viral load in steady state after seroconversion, which is probably the main reason for the poorer prognosis observed in this group of patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9358103     DOI: 10.1097/00042560-199710010-00004

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr Hum Retrovirol        ISSN: 1077-9450


  8 in total

1.  Precise determination of time to reach viral load set point after acute HIV-1 infection.

Authors:  Xiaojie Huang; Hui Chen; Wei Li; Haiying Li; Xia Jin; Alan S Perelson; Zoe Fox; Tong Zhang; Xiaoning Xu; Hao Wu
Journal:  J Acquir Immune Defic Syndr       Date:  2012-12-01       Impact factor: 3.731

2.  Role of avidity and breadth of the CD4 T cell response in progression to AIDS.

Authors:  Hester Korthals Altes; Rob de Boer; Maarten Boerlijst
Journal:  Proc Biol Sci       Date:  2006-07-07       Impact factor: 5.349

3.  The race between initial T-helper expansion and virus growth upon HIV infection influences polyclonality of the response and viral set-point.

Authors:  H Korthals Altes; R M Ribeiro; R J de Boer
Journal:  Proc Biol Sci       Date:  2003-07-07       Impact factor: 5.349

4.  Cost-effectiveness of HIV screening in patients older than 55 years of age.

Authors:  Gillian D Sanders; Ahmed M Bayoumi; Mark Holodniy; Douglas K Owens
Journal:  Ann Intern Med       Date:  2008-06-17       Impact factor: 25.391

Review 5.  Primary HIV Infection.

Authors:  Joanne Stekler; Ann C Collier
Journal:  Curr HIV/AIDS Rep       Date:  2004-06       Impact factor: 5.495

6.  Treatment of Primary HIV.

Authors:  Joanne Stekler; Ann Collier
Journal:  Curr Infect Dis Rep       Date:  2002-02       Impact factor: 3.663

7.  Clinical prognostic value of RNA viral load and CD4 cell counts during untreated HIV-1 infection--a quantitative review.

Authors:  Eline L Korenromp; Brian G Williams; George P Schmid; Christopher Dye
Journal:  PLoS One       Date:  2009-06-17       Impact factor: 3.240

8.  Prediction of extended high viremia among newly HIV-1-infected persons in sub-Saharan Africa.

Authors:  Kimberly A Powers; Matthew A Price; Etienne Karita; Anatoli Kamali; William Kilembe; Susan Allen; Eric Hunter; Linda-Gail Bekker; Shabir Lakhi; Mubiana Inambao; Omu Anzala; Mary H Latka; Patricia E Fast; Jill Gilmour; Eduard J Sanders
Journal:  PLoS One       Date:  2018-04-03       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.